Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about VKTX stock here.

In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...